Status: Recruiting
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies. Anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors. This study is to investigate the combination of Leuprorelin ADT and Sintilimab (anti-PD-1) therapy in patients with advanced lung cancer.
Participants needed: 80
Trial details
Age: 60+Biological sex: MaleType: InterventionalSponsor: Jinzhou Medical UniversityUpdated: Sep 9, 2025Locations: 1
Eligibility criteria
Male patients aged ≥60 years. [+11]
Exclusion of cases that do not meet the inclusion criteria